Veterinary Medicines

ZIPYRAN PLUS tabletes suņiem

Authorised
  • Febantel
  • Praziquantel
  • Pyrantel embonate
Download as PDF

Product identification

Medicine name:
ZIPYRAN PLUS tabletes suņiem
Active substance:
  • Febantel
  • Praziquantel
  • Pyrantel embonate
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Febantel
    150.00
    milligram(s)
    /
    1.00
    Tablet
  • Praziquantel
    50.00
    milligram(s)
    /
    1.00
    Tablet
  • Pyrantel embonate
    50.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP52AA51
Legal status of supply:
  • Veterinary medicinal product not subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Latvia
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Legal basis reviewed according to Acquis communautaire
Marketing authorisation holder:
  • Laboratorios Calier S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Laboratorios Calier S.A.
Responsible authority:
  • PVD
Authorisation number:
  • V/NRP/02/1520
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Latvian (PDF)
Published on: 7/03/2024
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Latvian (PDF)
Published on: 7/03/2024
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Latvian (PDF)
Published on: 7/03/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."